Arcellx News

Gilead (GILD.US) /ArcellX's Next-Generation BCMA CAR-T Launches Phase III Clinical Trial

Gilead (GILD.US) and ArcellX registered a phase III clinical trial of Anitocabtagene Autoleucel for the treatment of recurrent or refractory multiple myeloma on the ClinicalTrials.gov website.

Zhitong FinanceMay 16 08:10

Arcellx Is Maintained at Buy by Stifel

Arcellx Is Maintained at Buy by Stifel

Dow JonesMay 15 05:58

Stifel: Maintaining the Arcellx (ACLX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $82.00 to $83.00.

Stifel: Maintaining the Arcellx (ACLX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $82.00 to $83.00.

Zhitong FinanceMay 15 05:50

Stifel Maintains Buy on Arcellx, Raises Price Target to $83

Stifel analyst Benjamin Burnett maintains Arcellx (NASDAQ:ACLX) with a Buy and raises the price target from $82 to $83.

BenzingaMay 15 05:47

Truist Financial Reaffirms Their Buy Rating on Arcellx Inc (ACLX)

TipRanksMay 14 09:05

Analyst Expectations For Arcellx's Future

During the last three months, 14 analysts shared their evaluations of Arcellx (NASDAQ:ACLX), revealing diverse outlooks from bullish to bearish.The following table summarizes their recent ratings, she

BenzingaMay 14 07:01

Arcellx Initiated at Outperform by Evercore ISI Group

Arcellx Initiated at Outperform by Evercore ISI Group

Dow JonesMay 14 04:29

Arcellx (ACLX.US) was first covered by Evercore ISI Group, which gave it an superior market rating, with a target price of $85.00.

Arcellx (ACLX.US) was first covered by Evercore ISI Group, which gave it an superior market rating, with a target price of $85.00.

Zhitong FinanceMay 14 04:21

Evercore ISI Group Initiates Coverage On Arcellx With Outperform Rating, Announces Price Target of $85

Evercore ISI Group analyst Cory Kasimov initiates coverage on Arcellx (NASDAQ:ACLX) with a Outperform rating and announces Price Target of $85.

BenzingaMay 14 04:18

Buy Rating for Arcellx Inc. on Promising CAR-T Cell Therapy Trials and Strategic Market Positioning

TipRanksMay 14 03:46

Arcellx Price Target Cut to $80.00/Share From $82.00 by HC Wainwright & Co.

Arcellx Price Target Cut to $80.00/Share From $82.00 by HC Wainwright & Co.

Dow JonesMay 13 12:50

Arcellx Is Maintained at Buy by HC Wainwright & Co.

Arcellx Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 13 12:50

HC Wainwright & Co. Maintains Buy on Arcellx, Lowers Price Target to $80

HC Wainwright & Co. analyst Emily Bodnar maintains Arcellx (NASDAQ:ACLX) with a Buy and lowers the price target from $82 to $80.

BenzingaMay 13 12:41

Buy Rating Affirmed for Arcellx Inc. Amidst Promising Trial Progress and Strategic Partnerships

TipRanksMay 13 02:15

Arcellx, Inc. (NASDAQ:ACLX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Arcellx, Inc. (NASDAQ:ACLX) just released its quarterly report and things are looking bullish. The results were impressive, with revenues of US$39m exceeding analyst forecasts by 90%, and statuto

Simply Wall StMay 12 09:03

Arcellx First Quarter 2024 Earnings: Beats Expectations

Yahoo FinanceMay 12 07:49

Needham: Reiterates Arcellx (ACLX.US) rating and adjusted from buy to buy rating, target price is $81.00.

Needham: Reiterates Arcellx (ACLX.US) rating and adjusted from buy to buy rating, target price is $81.00.

Zhitong FinanceMay 10 14:31

Needham Reiterates Buy on Arcellx, Maintains $81 Price Target

Needham analyst Gil Blum reiterates Arcellx (NASDAQ:ACLX) with a Buy and maintains $81 price target.

BenzingaMay 10 14:29

Arcellx Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 64.42% Needham → $81 Reiterates Buy → Buy 05/07/2024 64.42% Needham → $81 Reiterates Buy → Buy

BenzingaMay 10 14:28

Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge

Yahoo FinanceMay 10 12:13